BioXcel Therapeutics, Inc. also files under BTAI ]; those filings are included.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | Atkins Susan E. | Director | Grant(A) | 17K | — | $0 |
| Jun 15, 2026 | Yocca Frank | Chief Scientific Officer | Option exercise(M) | 35 | — | — |
| Jun 15, 2026 | Yocca Frank | Chief Scientific Officer | Option exercise(M) | 35 | — | $0 |
| Jun 15, 2026 | Rodriguez Javier | See Remarks | Option exercise(M) | 35 | — | $0 |
| Jun 15, 2026 | Mehta Vimal | CEO and President, Director | Option exercise(M) | 219 | — | $0 |
| Jun 15, 2026 | Rodriguez Javier | See Remarks | Option exercise(M) | 35 | — | — |
| Jun 15, 2026 | Mehta Vimal | CEO and President, Director | Option exercise(M) | 219 | — | — |
| Jun 15, 2026 | Steinhart Richard I | Chief Financial Officer | Option exercise(M) | 35 | — | — |
| Jun 15, 2026 | Steinhart Richard I | Chief Financial Officer | Option exercise(M) | 35 | — | $0 |
| May 20, 2026 | Rodriguez Javier | See Remarks | Sell(S) | 7K | $1.08 | $7K |
| May 20, 2026 | Steinhart Richard I | Chief Financial Officer | Sell(S) | 7K | $1.09 | $7K |
| May 20, 2026 | Mehta Vimal | CEO and President, Director | Sell(S) | 19K | $1.09 | $21K |
| May 20, 2026 | Yocca Frank | Chief Scientific Officer | Sell(S) | 7K | $1.09 | $7K |
| May 4, 2026 | Mehta Vimal | CEO and President, Director | Option exercise(M) | 50K | — | $0 |
| May 4, 2026 | Steinhart Richard I | Chief Financial Officer | Option exercise(M) | 18K | — | $0 |
| May 4, 2026 | Yocca Frank | Chief Scientific Officer | Option exercise(M) | 18K | — | $0 |
| May 4, 2026 | Rodriguez Javier | See Remarks | Option exercise(M) | 18K | — | $0 |
| May 4, 2026 | Steinhart Richard I | Chief Financial Officer | Option exercise(M) | 18K | — | — |
| May 4, 2026 | Mehta Vimal | CEO and President, Director | Option exercise(M) | 50K | — | — |
| May 4, 2026 | Yocca Frank | Chief Scientific Officer | Option exercise(M) | 18K | — | — |
| May 4, 2026 | Rodriguez Javier | See Remarks | Option exercise(M) | 18K | — | — |
| May 1, 2026 | Steinhart Richard I | Chief Financial Officer | Option exercise(M) | 9K | — | $0 |
| May 1, 2026 | Mehta Vimal | CEO and President, Director | Option exercise(M) | 18K | — | — |
| May 1, 2026 | Yocca Frank | Chief Scientific Officer | Option exercise(M) | 9K | — | — |
| May 1, 2026 | Rodriguez Javier | See Remarks | Option exercise(M) | 9K | — | — |
| May 1, 2026 | Steinhart Richard I | Chief Financial Officer | Option exercise(M) | 9K | — | — |
| May 1, 2026 | Yocca Frank | Chief Scientific Officer | Option exercise(M) | 9K | — | $0 |
| May 1, 2026 | Mehta Vimal | CEO and President, Director | Option exercise(M) | 18K | — | $0 |
| May 1, 2026 | Rodriguez Javier | See Remarks | Option exercise(M) | 9K | — | $0 |
| Mar 15, 2026 | Yocca Frank | Chief Scientific Officer | Option exercise(M) | 35 | — | $0 |
| Mar 15, 2026 | Mehta Vimal | CEO and President, Director | Option exercise(M) | 219 | — | $0 |
| Mar 15, 2026 | Yocca Frank | Chief Scientific Officer | Option exercise(M) | 35 | — | — |
| Mar 15, 2026 | Mehta Vimal | CEO and President, Director | Option exercise(M) | 219 | — | — |
| Mar 15, 2026 | Steinhart Richard I | Chief Financial Officer | Option exercise(M) | 35 | — | $0 |
| Mar 15, 2026 | Steinhart Richard I | Chief Financial Officer | Option exercise(M) | 35 | — | — |
| Mar 15, 2026 | Rodriguez Javier | See Remarks | Option exercise(M) | 35 | — | $0 |
| Mar 15, 2026 | Rodriguez Javier | See Remarks | Option exercise(M) | 35 | — | — |
| Mar 14, 2026 | Yocca Frank | Chief Scientific Officer | Option exercise(M) | 33 | — | $0 |
| Mar 14, 2026 | Mehta Vimal | CEO and President, Director | Option exercise(M) | 164 | — | $0 |
| Mar 14, 2026 | Mehta Vimal | CEO and President, Director | Option exercise(M) | 164 | — | — |
| Mar 14, 2026 | Yocca Frank | Chief Scientific Officer | Option exercise(M) | 33 | — | — |
| Mar 14, 2026 | Steinhart Richard I | Chief Financial Officer | Option exercise(M) | 33 | — | $0 |
| Mar 14, 2026 | Steinhart Richard I | Chief Financial Officer | Option exercise(M) | 33 | — | — |
| Mar 14, 2026 | Rodriguez Javier | See Remarks | Option exercise(M) | 33 | — | $0 |
| Mar 14, 2026 | Rodriguez Javier | See Remarks | Option exercise(M) | 33 | — | — |
| Jan 9, 2026 | Miller Michael Patrick | Director | Grant(A) | 17K | — | $0 |
| Jan 9, 2026 | Bray June | Director | Grant(A) | 17K | — | $0 |
| Jan 9, 2026 | Laumas Sandeep | Director | Grant(A) | 17K | — | $0 |
| Jan 9, 2026 | Patni Rajiv | Director | Grant(A) | 17K | — | $0 |
| Jan 9, 2026 | Mack David J. | Director | Grant(A) | 17K | — | $0 |
| Jan 9, 2026 | Mueller Peter | Director | Grant(A) | 17K | — | $0 |
| Jan 9, 2026 | Votruba Michal | Director | Grant(A) | 17K | — | $0 |
| Jan 1, 2026 | Rodriguez Javier | See Remarks | Grant(A) | 70K | — | $0 |
| Jan 1, 2026 | Steinhart Richard I | Chief Financial Officer | Grant(A) | 70K | — | $0 |
| Jan 1, 2026 | Mehta Vimal | CEO and President, Director | Grant(A) | 199K | — | $0 |
| Jan 1, 2026 | Yocca Frank | Chief Scientific Officer | Grant(A) | 70K | — | $0 |
| Dec 15, 2025 | Mehta Vimal | CEO and President, Director | Option exercise(M) | 219 | — | $0 |
| Dec 15, 2025 | Mehta Vimal | CEO and President, Director | Option exercise(M) | 219 | — | — |
| Dec 15, 2025 | Steinhart Richard I | Chief Financial Officer | Option exercise(M) | 35 | — | $0 |
| Dec 15, 2025 | Steinhart Richard I | Chief Financial Officer | Option exercise(M) | 35 | — | — |
| Dec 15, 2025 | Rodriguez Javier | See Remarks | Option exercise(M) | 35 | — | $0 |
| Dec 15, 2025 | Rodriguez Javier | See Remarks | Option exercise(M) | 35 | — | — |
| Dec 15, 2025 | Yocca Frank | Chief Scientific Officer | Option exercise(M) | 35 | — | $0 |
| Dec 15, 2025 | Yocca Frank | Chief Scientific Officer | Option exercise(M) | 35 | — | — |
| Dec 14, 2025 | Mehta Vimal | CEO and President, Director | Option exercise(M) | 164 | — | $0 |
| Dec 14, 2025 | Mehta Vimal | CEO and President, Director | Option exercise(M) | 164 | — | — |
| Dec 14, 2025 | Steinhart Richard I | Chief Financial Officer | Option exercise(M) | 33 | — | — |
| Dec 14, 2025 | Steinhart Richard I | Chief Financial Officer | Option exercise(M) | 33 | — | $0 |
| Dec 14, 2025 | Rodriguez Javier | See Remarks | Option exercise(M) | 33 | — | $0 |
| Dec 14, 2025 | Rodriguez Javier | See Remarks | Option exercise(M) | 33 | — | — |
| Dec 14, 2025 | Yocca Frank | Chief Scientific Officer | Option exercise(M) | 33 | — | $0 |
| Dec 14, 2025 | Yocca Frank | Chief Scientific Officer | Option exercise(M) | 33 | — | — |
| Oct 31, 2025 | Mack David J. | Director | Option exercise(M) | 2K | — | $0 |
| Oct 31, 2025 | Mack David J. | Director | Option exercise(M) | 2K | — | — |
| Sep 30, 2025 | Mack David J. | Director | Option exercise(M) | 2K | — | $0 |
| Sep 30, 2025 | Mack David J. | Director | Option exercise(M) | 2K | — | — |
| Sep 15, 2025 | Mehta Vimal | CEO and President, Director | Option exercise(M) | 219 | — | $0 |
| Sep 15, 2025 | Mehta Vimal | CEO and President, Director | Option exercise(M) | 219 | — | — |
| Sep 15, 2025 | Steinhart Richard I | Chief Financial Officer | Option exercise(M) | 35 | — | $0 |
| Sep 15, 2025 | Steinhart Richard I | Chief Financial Officer | Option exercise(M) | 35 | — | — |
| Sep 15, 2025 | Rodriguez Javier | See Remarks | Option exercise(M) | 35 | — | $0 |
| Sep 15, 2025 | Yocca Frank | Chief Scientific Officer | Option exercise(M) | 35 | — | — |
| Sep 15, 2025 | Rodriguez Javier | See Remarks | Option exercise(M) | 35 | — | — |
| Sep 15, 2025 | Yocca Frank | Chief Scientific Officer | Option exercise(M) | 35 | — | $0 |
| Sep 14, 2025 | Yocca Frank | Chief Scientific Officer | Option exercise(M) | 33 | — | — |
| Sep 14, 2025 | Mehta Vimal | CEO and President, Director | Option exercise(M) | 163 | — | $0 |
| Sep 14, 2025 | Mehta Vimal | CEO and President, Director | Option exercise(M) | 163 | — | — |
| Sep 14, 2025 | Steinhart Richard I | Chief Financial Officer | Option exercise(M) | 33 | — | $0 |
| Sep 14, 2025 | Steinhart Richard I | Chief Financial Officer | Option exercise(M) | 33 | — | — |
| Sep 14, 2025 | Rodriguez Javier | See Remarks | Option exercise(M) | 33 | — | $0 |
| Sep 14, 2025 | Rodriguez Javier | See Remarks | Option exercise(M) | 33 | — | — |
| Sep 14, 2025 | Yocca Frank | Chief Scientific Officer | Option exercise(M) | 33 | — | $0 |
| Aug 31, 2025 | Mack David J. | Director | Option exercise(M) | 2K | — | $0 |
| Aug 31, 2025 | Mack David J. | Director | Option exercise(M) | 2K | — | — |
| Aug 1, 2025 | Steinhart Richard I | Chief Financial Officer | Grant(A) | 9K | — | $0 |
| Aug 1, 2025 | Rodriguez Javier | See Remarks | Grant(A) | 9K | — | $0 |
| Aug 1, 2025 | Yocca Frank | Chief Scientific Officer | Grant(A) | 9K | — | $0 |
| Aug 1, 2025 | Mehta Vimal | CEO and President, Director | Grant(A) | 18K | — | $0 |
| Jul 31, 2025 | Mack David J. | Director | Option exercise(M) | 2K | — | $0 |
| Jul 31, 2025 | Mack David J. | Director | Option exercise(M) | 2K | — | — |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: BioXcel Therapeutics, Inc., SEC CIK 0001720893. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under BTAI and shows every filing by that issuer (also filed as BTAI ]).
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-12. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for BTAI